Pemphigus foliaceus (PF) is an autoimmune blistering skin disease characterized by superficial epidermal blisters and the production of pathogenic autoantibodies directed against desmoglein 1, a 160-kDa transmembrane desmosomal glycoprotein belonging to the cadherin superfamily.
Pemphigus foliaceus (PF) is an autoimmune blistering skin disease characterized by superficial epidermal blisters and the production of pathogenic autoantibodies directed against desmoglein 1, a 160-kDa transmembrane desmosomal glycoprotein belonging to the cadherin superfamily. 1 Two different varieties of PF have been identified. The sporadic form occurs in western Europe and North America with a low incidence (Ͻ1 case per million per year) and equally affects males and females over 50 years old. 2 The endemic form is observed in different geographic regions particularly in Brazil and Tunisia, and has different epidemiological characteristics. 3 In Brazil, PF is known as folgo selvagem (FS), has a high incidence (25 cases per million per year) and predominantly affects young adults with no sex predominance. In Tunisia, PF is mainly observed in females р35 years old, among which the incidence rate reaches 15 cases per million per year. 2, 3 Patients with sporadic or endemic PF synthesize autoantibodies with similar immunochemical properties and frequently bear the same HLA class II alleles (DRB1*0102 and DRB1*0404), 4, 5 The results of our recent case-control study performed on French Caucasian patients and healthy controls showed that the desmoglein 1 gene (DSG1) is polymorphic and that one of its variants is associated with sporadic PF. 6 This observation prompted us to determine whether the endemic form of PF seen in Tunisia is also associated with this polymorphic variant of DSG1.
Forty-nine Tunisian PF patients (10 males and 39 females; mean age 40 ± 13.5 years, range: 18-68) were recruited in the Dermatology Departments of Tunis and Sfax university hospitals, from January 1998 to December 2000. They all fulfilled the clinical, histological and immunological criteria of PF. 7 The control population consisted of 141 Tunisian healthy blood donors (72 males and 69 females; mean age 31 years, range: 20-60).
Two polymorphic markers were previously identified in DSG1 :
6 a variant haplotype of five missense mutations located in exon 11, ie, on the part of the gene encoding the extracellular domains 4 and 5; and a single T to C substitution at position 809 in the region of exon 7 encoding extracellular domain 2. Only the T/C (809) single nucleotide polymorphism (SNP) was found to be involved in the sporadic PF observed in France which was associated with the presence of a cytosine at position 809 and, more strongly, with the C/C genotype of SNP (809). 6 Thus, in the present study, we focused our analysis on the exon 7 polymorphism, using a PCR digestion technique that takes advantage of the FauI restriction site created by the presence of a cytosine at position 809 ( Figure 1) .
The distribution of the C/T (809) SNP in Tunisian PF patients and healthy controls is reported in Table 1 . The allele frequencies of the C (809) were close to those observed in French PF patients (65%) and controls (48%) and, although the C (809) allele frequency was higher in Tunisian PF patients than in controls, the difference did not reach significance (P = 0.09). This trend prompted us to compare the distribution of SNP (809) genotypes and especially the C/C (809) genotype in patients and controls. Significantly more patients had the homozygous C/C (809) genotype, indicating that the cytosine at position (809) SNP exerts its effect when present at the homozygous state. This finding is reminiscent of that observed in sporadic French PF, 6 and suggests that the homozygous state facilitates the penetrance of the trait.
The demonstration that a polymorphic variant of DSG1 is associated with the sporadic and endemic forms of PF, and the recent observation that both PF forms share common HLA class II alleles 4, 5 indicate that common genetic factors govern the breakage of B-and T-cell tolerance to desmoglein 1 in different epidemiological situations.
